FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3154354258> ?p ?o ?g. }

• W3154354258 endingPage "304" @default.
• W3154354258 startingPage "293" @default.
• W3154354258 abstract "Haemophagocytic lymphohistiocytosis (HLH) is a severe disorder with high mortality. The aim of this review is to update clinical management of relapsed/refractory HLH in adults, with a focus on current and new therapies.We searched relevant articles in Embase and PUBMED with the MESH term hemophagocytic lymphohistiocytosis; refractory; relapsing; adult.One hundred eight papers were found; of these, 22 were retained for this review. The treatment of HLH in adult is based on the HLH-94 regimen. The response rate is lower than in pediatric patients, and 20-30% are refractory to this therapy. DEP regimen and allogenic hematopoietic stem cell transplantation (HSCT) are associated with complete response and partial response in 27% and 49.2%, respectively. However, many patients fail to achieve a stable condition before HSCT, and mortality is higher in them. New drugs have been developed, such as emapalumab, ruxolitinib, and alemtuzumab, and they may be used as bridges to the curative HSCT. They are relatively well tolerated and have few or mild side effects. With these agents, the rate of partial response ranges from 14.2% to 100%, while the rate of complete response is highly variable according to study and medication used. The number of patients who achieved HSCT ranged from 44.8% to 77%, with a survival rate of 55.9% to 100%. However, the populations in these studies are mainly composed of mixed-age patients (pediatric and adult patients), and studies including only adult patients are scarce.Relapsed or refractory HLH in adult patients is associated with poor outcome, and consolidation with HSCT may be required in some cases. Mortality related to HSCT is mainly due to active HLH disease before HSCT and post HSCT complications. New drugs, such as empalumab, ruxolitinib, and alemtuzumab are interesting since these agents may be used as bridges to HSCT with increases in the numbers of patients proceeding to HSCT and survival rate." @default.
• W3154354258 created "2021-04-26" @default.
• W3154354258 creator A5027749653 @default.
• W3154354258 creator A5044654238 @default.
• W3154354258 creator A5050079005 @default.
• W3154354258 creator A5062754596 @default.
• W3154354258 date "2021-04-01" @default.
• W3154354258 modified "2023-10-16" @default.
• W3154354258 title "Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies" @default.
• W3154354258 cites W1502651188 @default.
• W3154354258 cites W1505641753 @default.
• W3154354258 cites W1574141134 @default.
• W3154354258 cites W1908769349 @default.
• W3154354258 cites W2013243341 @default.
• W3154354258 cites W2013522127 @default.
• W3154354258 cites W2015286386 @default.
• W3154354258 cites W2023033734 @default.
• W3154354258 cites W2029693047 @default.
• W3154354258 cites W2064037171 @default.
• W3154354258 cites W2075395334 @default.
• W3154354258 cites W2085894509 @default.
• W3154354258 cites W2088301075 @default.
• W3154354258 cites W2088419428 @default.
• W3154354258 cites W2090202760 @default.
• W3154354258 cites W2100649672 @default.
• W3154354258 cites W2102924822 @default.
• W3154354258 cites W2111390975 @default.
• W3154354258 cites W2120380892 @default.
• W3154354258 cites W2133944586 @default.
• W3154354258 cites W2138508661 @default.
• W3154354258 cites W2153039996 @default.
• W3154354258 cites W2155477306 @default.
• W3154354258 cites W2163067702 @default.
• W3154354258 cites W2164721732 @default.
• W3154354258 cites W2208498818 @default.
• W3154354258 cites W2220882815 @default.
• W3154354258 cites W2282216981 @default.
• W3154354258 cites W2282446718 @default.
• W3154354258 cites W2295201085 @default.
• W3154354258 cites W2400128945 @default.
• W3154354258 cites W2408847959 @default.
• W3154354258 cites W2417595397 @default.
• W3154354258 cites W2444620062 @default.
• W3154354258 cites W2462569384 @default.
• W3154354258 cites W2511457717 @default.
• W3154354258 cites W2515871717 @default.
• W3154354258 cites W2593544935 @default.
• W3154354258 cites W2620888767 @default.
• W3154354258 cites W2625802019 @default.
• W3154354258 cites W2747246083 @default.
• W3154354258 cites W2751903471 @default.
• W3154354258 cites W2794711063 @default.
• W3154354258 cites W2802308299 @default.
• W3154354258 cites W2807441801 @default.
• W3154354258 cites W2811067466 @default.
• W3154354258 cites W2884397450 @default.
• W3154354258 cites W2904894901 @default.
• W3154354258 cites W2920958771 @default.
• W3154354258 cites W2925026141 @default.
• W3154354258 cites W2936019126 @default.
• W3154354258 cites W2949013397 @default.
• W3154354258 cites W2973195305 @default.
• W3154354258 cites W2973341403 @default.
• W3154354258 cites W2974630541 @default.
• W3154354258 cites W2983311648 @default.
• W3154354258 cites W2999041872 @default.
• W3154354258 cites W3000471804 @default.
• W3154354258 cites W3004481399 @default.
• W3154354258 cites W3021363743 @default.
• W3154354258 cites W3023366480 @default.
• W3154354258 cites W3035147924 @default.
• W3154354258 cites W3044095987 @default.
• W3154354258 cites W3048513059 @default.
• W3154354258 cites W3097821002 @default.
• W3154354258 cites W3107849551 @default.
• W3154354258 cites W3112059656 @default.
• W3154354258 cites W3119959898 @default.
• W3154354258 cites W4241263512 @default.
• W3154354258 doi "https://doi.org/10.2147/tcrm.s195538" @default.
• W3154354258 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8056168" @default.
• W3154354258 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33888986" @default.
• W3154354258 hasPublicationYear "2021" @default.
• W3154354258 type Work @default.
• W3154354258 sameAs 3154354258 @default.
• W3154354258 citedByCount "20" @default.
• W3154354258 countsByYear W31543542582021 @default.
• W3154354258 countsByYear W31543542582022 @default.
• W3154354258 countsByYear W31543542582023 @default.
• W3154354258 crossrefType "journal-article" @default.
• W3154354258 hasAuthorship W3154354258A5027749653 @default.
• W3154354258 hasAuthorship W3154354258A5044654238 @default.
• W3154354258 hasAuthorship W3154354258A5050079005 @default.
• W3154354258 hasAuthorship W3154354258A5062754596 @default.
• W3154354258 hasBestOaLocation W31543542581 @default.
• W3154354258 hasConcept C121332964 @default.
• W3154354258 hasConcept C126322002 @default.
• W3154354258 hasConcept C142424586 @default.
• W3154354258 hasConcept C187212893 @default.

• next